Unilever’s unexpected pursuit of GlaxoSmithKline’s Consumer Healthcare business appears to be over, with the London-based firm confirming it would not submit a higher bid than its rejected £50bn ($68bn) cash and shares offer.
New information published by GSK since that failed bid outlining the medium-term growth prospects for Consumer Healthcare has failed to...







